Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
USA118th CongressHR-3884| House
| Updated: 9/24/2024
Michael C. Burgess
Republican Representative
Texas
Cosponsors (3)
Health, Education, Labor, and Pensions Committee, Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Subcommittee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 28 - 0.
Committee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended) by the Yeas and Nays: 50 - 0.
Placed on the Union Calendar, Calendar No. 132.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-166.
Latest Companion Bill Action
S 118-1852Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders without amendment. Without written report.
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5578-5580)
DEBATE - The House proceeded with forty minutes of debate on H.R. 3884.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
Blood and blood diseasesHealth programs administration and fundingHealth promotion and preventive careHereditary and development disordersMedical research
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
USA118th CongressHR-3884| House
| Updated: 9/24/2024
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Subcommittee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 28 - 0.
Committee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended) by the Yeas and Nays: 50 - 0.
Placed on the Union Calendar, Calendar No. 132.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-166.
Latest Companion Bill Action
S 118-1852Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders without amendment. Without written report.
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5578-5580)
DEBATE - The House proceeded with forty minutes of debate on H.R. 3884.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Michael C. Burgess
Republican Representative
Texas
Cosponsors (3)
Health, Education, Labor, and Pensions Committee, Health Subcommittee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Blood and blood diseasesHealth programs administration and fundingHealth promotion and preventive careHereditary and development disordersMedical research